Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg-Reference-Cited by-同舟云学术

Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg

Published:2022-03-09 Issue:4 Volume:38 Page:333-338
ISSN:0951-3590
Container-title:Gynecological Endocrinology
language:en
Short-container-title:Gynecological Endocrinology

Author:

Regidor Pedro-Antonio¹^ORCID,Palacios Santiago²,Colli Enrico³

Affiliation:

1. Exeltis Europe, Ismaning, Germany

2. Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain

3. Exeltis HealthCare Madrid, Madrid, Spain

Publisher

Informa UK Limited

Subject

Obstetrics and Gynecology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.1080/09513590.2022.2046729

Reference27 articles.

1. Reprint of Classification and pharmacology of progestins

2. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day

3. PRAC referral assessment report. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. Combined hormonal contraceptives containing medicinal products INN: chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate. 2013. Procedure No. EMEA/H/A-31/1356.

4. WHO Medical eligibility criteria for contraceptive use. 5th ed. 2015; 47–61.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quelles nouveautés en contraception féminine ?;Gynécologie Obstétrique Fertilité & Sénologie ;2024-01

2. A new progestin-only pill (POP): the impact of drospirenone-only pill 4 mg 24 + 4 on coagulation markers and bleeding patterns;The European Journal of Contraception & Reproductive Health Care;2023-11-02

3. The drospirenone (DRSP)-only pill: clinical implications in the daily use;The European Journal of Contraception & Reproductive Health Care;2023-01-02

4. Drospirenone 4 mg in a 24 + 4 regimen in women with contraindications to oestrogen use for contraception: bleeding patterns according to previous menstrual characteristics;Archives of Gynecology and Obstetrics;2022-11-21